Inhibition of angiogenesis and murine tumour growth by laminarin sulphate

British Journal of Cancer

Volumn 73, Issue 10, 1996, Pages 1183-1186

  Hoffman, R ^a,c   Paper, D H ^b   Donaldson, J ^a   Vogl, H ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Angiogenesis; Anti tumour; Laminarin sulphate

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; LAM S5; LAMINARAN; LAMINARIN SULPHATE; MELPHALAN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CATTLE; CELL CULTURE; CELL PROLIFERATION; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; FETUS; HEART; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICROTUBULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VASCULARIZATION;

EID: 0029946181     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.228     Document Type: Article

References (26)

1. ADES EW, CANDAL FJ, SWERLICK RA, GEORGE VG, SUMMERS S, BOSSE DC AND LAWLEY TJ. (1992). HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol., 99, 683-690.
2. ALBAN S, KRAUS L AND FRANZ G. (1992). Synthesis of laminarin sulphates with anti-coagulant activity. Arzneim-Forsch, 42(II): 1005-1008.
3. 3. Cancer Chemo. Pharmacol., 34, 175-178.
4. CASU B AND GENNARO U. (1975). A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides. Carbohydrate Res. 39, 168-176.
5. CRUM R, SZABO S AND FOLKMAN J. (1985). A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science, 230, 1375-1378.
6. FOLKMAN J. (1975). Tumour angiogenesis. Adv. Cancer Res., 43, 175-203.
7. FOLKMAN J AND KLAGSBRUN M. (1987). Angiogenic factors. Science, 235, 442-447.
8. FOLKMAN J, LANGAR R, LINHARDT RJ, HAUDENSCHILD C AND TAYLOR S. (1983). Angiogenesis inhibition and tumour regression caused by heparin or a heparin fragment in the presence of cortisone. Science, 221, 719-725.
9. HOFFMAN R, PAPER DH, DONALDSON J, ALBAN S AND FRANZ G. (1995a). Characterisation of a laminarin sulphate which inhibits basic fibroblast growth factor binding and endothelial cell proliferation. J. Cell Sci., 108, 3591-3598.
10. HOFFMAN R, BURNS WW AND PAPER DH. (1995b). Selective inhibition of cell proliferation and DNA synthesis by the polysulphated carbohydate l-carrageenan. Cancer Chemo. Pharmacol., 36, 325-334.
11. HONESS DJ AND BLEEHEN NM. (1985). Thermochemotheraphy with cis-platinum, CCNU, BCNU, chlorambucil and melphalan on murine marrow and two tumours: therapeutic gain for melphalan only. Brit. J. Radiol., 58, 63-72.
12. JAKOBSON AM, HAHNENBERGER R AND MAGNUSSON A. (1989). A simple method for shell-less cultivation of chick embryos. Pharmacol. Toxicol., 64, 193-195.
13. MURATA J, SAIKI I, MAKABE T, TSUTA Y, TOKURA S AND AZUMA I. (1991). Inhibition of tumour-induced angiogenesis by sulphated chitin derivatives. Cancer Res., 51, 22-26.
14. NAKAYAMA Y, IWAHANA M, SAKAMOTO N, TANAKA NG AND OSADA Y. (1993). Inhibitory effects of a bacteria-derived sulphated polysaccharide against basic fibroblast growth factor-induced endothelial cell growth and chemotaxis. J. Cell Physiol., 154, 1-6.
15. NGUYEN M, WATANABE H, BUDSON AE, RICHIE JP, HAYES DF AND FOLKMAN J. (1994). Elevated levels of an angiogenic growth peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl Cancer Inst., 86, 356-361.
16. PENHALIGON M AND CAMPLEJOHN RS. (1985). Combination heparin plus cortisone treatment of two transplanted tumours in C3H/He mice. J. Natl Cancer Inst., 74, 869-873.
17. PESENTI E, SOLA F, MONGELLI N, GRANDI M AND SPREAFICO F. (1992). Suramin prevents neovascularization and tumour growth through blocking of basic fibroblast growth factor activity. Brit. J. Cancer, 66, 367-372.
18. PLUDA JM, SHAY LE, FOLI A, TANNENBAUM S, COHEN PJ, GOLDSPIEL BR, ADAMO D, COOPER MR, BRODER S AND YARCHOAN R. (1993). Administration of pentosan polysulphate to patients with human-immunodeficiency virus-associated Kaposi's sarcoma. J. Natl Cancer Inst., 85, 1585-1592.
19. SCOTT PAE AND HARRIS AL. (1994). Current approaches to targeting cancer using antiangiogenesis therapies. Cancer Treat. Revs., 20, 393-412.
20. TANAKA NG, SAKAMOTO N, INOUE K, KORENAGA H, KADOYA S, OGAWA H AND OSADA Y. (1989). Antitumour effects of an antiangiogenic polysaccharide from an Arthrobacter species with and without a steroid. Cancer Res., 49, 6727-6730.
21. TEICHER BA, SOTOMAYOR EA AND HUANG D. (1992). Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res., 52, 6702-6704.
22. THORPE PE, DERBYSHIRE EJ, ANDRADE SP, PRESS N, KNOWLES PP, KING S, WATSON GJ, YANG F-C AND RAO-BETTE M. (1993). Heparin-steroid conjugates: new angiogenesis inhibitors with anti-tumour activity in mice. Cancer Res., 53, 3000-3007.
23. TWENTYMAN PR, BROWN JM, GRAY JW, FRANKO AJ, SCOLES MA AND KALLMAN RF. (1980). A new mouse model tumour system (RIF-1) for comparison of end-point studies. J. Natl Cancer Inst., 64, 597-604.
24. UKCCCR. (1988). Guidelines for the welfare of animals in experimental neoplasia. UKCCCR, 20 Park Crescent, London, UK.
25. YAMANAKA Y, FRIESS H, BUCHLER M, BERGER HG, UCHIDA E, ONDA M, KOBRIN MS AND KORC M. (1993). Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumour stage. Cancer Res., 53, 5289-5296.
26. ZUGMAIER G, LIPPMAN M AND WELLSTEIN A. (1992). Inhibition by pentosan polysulphate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumour growth in animals. J. Natl Cancer. Inst., 84, 1716-1724.